Abstract
Pharmacogenomic studies on statins ranging from the candidate gene approach to the genome-wide studies in western populations have provided evidence that genetic variations play a limited role in determining statin responses. However, there are ethnic difference in the pharmacokinetics and safety of statins and due to the different frequencies of polymorphisms and different linkage disequilibrium patterns among the ethnic groups, the genetic markers identified in genome-wide association study platforms or in candidate gene studies in one population cannot always be generalized to other populations. This review provides an overview on the pharmacogenomics of statins in Chinese population.
Keywords::
Financial & competing interests disclosure
The authors were supported by a grant from the Food and Health Bureau (Project no. HHSRF 09100321) of the Hong Kong Special Administrative Region, China. The funding source had no role in the preparation of this manuscript. Tomlinson has received research funding to perform clinical studies from Abbott Laboratories Ltd, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck Serono, Merck Sharp and Dohme, Novartis, Roche and Takeda and has acted as a consultant or speaker on occasions for Amgen, AstraZeneca, Boehringer Ingelheim, Genzyme, Janssen, Merck Serono, Merck Sharp and Dohme, Ranbaxy and Servier. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.